EMA Authorised: Enurev Breezhaler (glycopyrronium bromide) — Novartis Europharm Ltd

View source ↗

Summary

The European Medicines Agency has authorized Enurev Breezhaler, containing glycopyrronium bromide, for the treatment of chronic obstructive pulmonary disease. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Enurev Breezhaler (glycopyrronium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Novartis Europharm Ltd. Decision date: 23/01/2026